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Leif I. Solberg, MD1
Research Division, HealthPartners Institute, Minneapolis, MN; 2Essentia Institute of Rural Health, Essentia Health,
Duluth, MN; 3Department of Translational Data Science and Informatics, Geisinger, Danville, PA
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Purpose	Both patients and clinicians have described discussions of potential opioid risks as challenging. This
study’s goal was to understand patient perspectives on discussing opioid risks with primary care
clinicians (PCCs).
Methods

 atients identified to be at elevated risk for problems with opioids (ie, opioid use disorder [OUD]
P
diagnosis, taking a medication for OUD, or having ≥3 opioid prescriptions in the last year) were
recruited from an integrated, Upper Midwest health system to participate in semi-structured qualitative
interviews. Interview questions aimed to better understand patient views on conversations about opioid
risks with PCCs and perceptions of OUD screening and treatment in primary care. Interviews were
analyzed using an inductive thematic analysis approach.

Results 	A total of 20 patients participated (mean age: 53.5 years; 65% male). Six themes emerged: 1) archetypes
of patient relationships with opioids (long-term opioid use, acute opioid use, OUD in treatment, OUD no
treatment) require different approaches in discussing opioid risks; 2) patients may develop their own
archetypes about PCCs and opioids; 3) these archetypes may help guide how conversations about
opioids are conducted (eg, PCC demeanor, terminology); 4) most patients believe that primary care is an
appropriate setting for opioid risk discussions; 5) patients may have limited awareness of the availability
and value of overdose rescue medications; and 6) handouts are more acceptable if perceived to come
from the PCC’s assessment instead of a computer.
Conclusions	Results suggest that patients generally perceive discussing opioid risks with PCCs acceptable. PCCs
should tailor opioid risk conversations to patients’ specific situations and needs. (J Patient Cent Res
Rev. 2022;9:253-262.)
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A

pproximately 68,000 Americans died from
opioid-related overdoses in 2020, a 37% increase
from 2019.1 The most effective treatments
for opioid use disorder (OUD) are OUD medications
(MOUDs) — methadone, buprenorphine/naloxone, and
extended-release naltrexone — which reduce opioid
cravings, relapse, and overdose.2 However, only about 1
in 5 people with OUD receive such treatment.3
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Increasing MOUD access for patients with OUD in
outpatient settings is one approach to help end the opioid
epidemic. Specifically, buprenorphine/naloxone can be
prescribed in office-based outpatient settings by clinicians
with a Drug Addiction Treatment Act of 2000 (DATA2000) waiver.4 People with substance use disorders may
be more willing to seek treatment in primary care settings
than at specialty drug or alcohol treatment centers,
likely because they perceive less stigma in seeking
care in primary care settings.5 However, relatively
few primary care clinicians (PCCs) have obtained
waivers, and of those waivered, many do not prescribe
buprenorphine/naloxone.4 Among both waivered and
nonwaivered clinicians, lack of time, training, resources,
and confidence are barriers to prescribing MOUDs.6
Encouraging PCCs to address opioid risks could increase
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treatment engagement, as recent data suggest that people
with substance use disorders who report being screened
by a health care provider are 3–4 times more likely to
receive treatment than those who are not screened.7
To address barriers to OUD care in primary care, our
team developed a shared decision-making (SDM) tool
embedded in the electronic health record (EHR) that
alerts PCCs when a patient may be at high risk for OUD
or overdose and offers support for screening, diagnosing,
and treatment (trial information available at https://
clinicaltrials.gov/ct2/show/NCT04198428). The primary
goal of this tool is to prompt discussions about opioid
risks and to promote appropriate screening and treatment.
Although PCCs acknowledge their responsibility in
discussing opioid risks with their patients,8 they also
find these conversations challenging.9 Some PCCs report
negative attitudes toward people on MOUDs (eg, they are
difficult, argumentative, manipulative, or undesirable in
clinical settings)6 and may avoid having conversations
with patients about OUD treatment when possible.10
Clinicians vary in how they communicate opioid risks
to patients, but the interpretations and impact of these
variations with patients in unclear.11,12
On the patient side, some literature suggests that people
who use opioids to manage chronic pain may perceive
discussions about opioid risks with PCCs as stigmatizing.13
Patients may not understand that having a substance use
disorder is not a moral choice, and they may be concerned
that PCCs will accuse them of inappropriate behavior
rather than approaching out of concern for their wellbeing. Patients also report lower satisfaction of and more
difficulty with encounters where clinicians and patients
disagree on an opioid management plan.14 Thus, PCCs
and patients may benefit in working together to minimize
opioid risks, but little is known about patients’ preferences
for language and settings for these conversations.
This study aimed to learn patient perspectives on how our
SDM tool may be received and to gain an understanding
of how PCCs might best approach opioid risk discussions
in primary care. We posed the following research
questions: 1) How do conversations about opioid risks
with PCCs typically go? 2) How do patients feel about
being screened or treated for OUD in primary care?
3) How do patients perceive different messages about
opioid risk? and 4) How do patients feel about receiving
a handout stating their risk? To answer these questions,
we conducted a series of semi-structured qualitative
interviews with patients whose clinical characteristics
would prompt the SDM tool in the EHR.
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METHODS

Study Setting and Design

This qualitative, preplanned substudy was conducted
during the design phase of a larger clinical trial
examining the effect of an EHR-linked SDM tool to
help PCCs screen, diagnose, and treat patients with
OUD. The intervention was implemented in a large
multispecialty care system with 600 PCCs practicing in
52 clinics in the metropolitan Minneapolis/St. Paul area
of Minnesota. The study was reviewed, approved, and
monitored by the HealthPartners institutional review
board (study A18-345).
Participants

Eligible study patients were identified for recruitment by
8 PCCs interviewed in the design phase8 for optimizing
the implementation and use of the SDM tool from the
larger clinical trial (https://clinicaltrials.gov/ct2/show/
NCT04198428). The research team pulled a list of
eligible patients from the EHR who would be targeted for
the SDM tool and 1) were at least 18 years old; 2) had a
primary care encounter with the identifying PCC within
6 months of the study invitation (between March and
October 2019); and 3) had an OUD diagnosis, were taking
a MOUD, or had ≥3 opioid prescriptions in the past year.
Patients who were prisoners or currently hospitalized
were ineligible. PCCs reviewed lists of patients who met
inclusion criteria and identified candidates who would be
inappropriate to contact. While PCCs were not required
to disclose reasoning for discretionary exclusion, possible
scenarios include declining physical health of patient,
complex psychosocial situations, or the clinician not
having a strong relationship with the patient (eg, had only
seen once or twice).
Research assistants mailed invitations to 59 patients and
followed up by phone to determine patient interest and
eligibility. Of the 59 patients, 37 (63%) were reached via
phone. Of these, 23 (62%) were scheduled for interviews,
12 (32%) declined participation, and 2 (5%) were
ineligible. In all 20 patients completed the interviews and
were included in the analysis. Data saturation was reached
after the 20th interview, and no additional interviews
were scheduled.15
Procedure

Semi-structured interviews were conducted, recorded,
and transcribed between December 2019 and March
2020 in-person or by phone with a research project
manager trained in qualitative interviewing. Interviews
lasted 20–30 minutes and followed a guide with 7 stem
questions about patients’ 1) relationships with their PCC;
2) experiences taking opioids; 3) past discussions and
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perceived importance of opioid risks with their PCCs;
4) discussing opioids with their PCCs at care encounters
for other complaints; 5) preferred OUD terminology (eg,
opioid problems, dependence, addiction, misuse); 6)
reactions to targeted messaging and SDM handouts; and
7) advice to PCCs for discussing opioid risks.
The research team debriefed after every 2–3 interviews
to identify important highlights relevant to the ongoing
SDM tool design, summarize immediate impressions,
and inform subsequent interviews. During the debrief
meetings, the team determined that data saturation was
reached after no new themes were heard.15
Analysis

Qualitative analysis was conducted using an inductive
thematic analysis approach.16,17 First, at least 2 study
team members (S.A.H., L.I.S., I.J.E., A.W.O., or K.M.R.)
independently read each transcript and highlighted
segments of text (ie, unit of analysis) relevant to the
study aims. One team member wrote a preliminary
summary of observations for each transcript, and these
observations were then reviewed and refined by the
larger team in the context of the respective transcript.
Consensus observations were coded and analyzed
using qualitative research software (NVivo 12, QSR
International) and then used, with the interview guide,
to generate a preliminary codebook. The codebook was
refined as analysis progressed and earlier interviews
were recoded as new codes were developed. After all
transcripts were coded, 2 team members (S.A.H. and
L.I.S.) independently reviewed the coded observations
and generated overall themes. Themes were compared
by the entire study team and edited and refined using a
group consensus process.

RESULTS

Participants (N=20) were, on average, 53.5 years old
(standard deviation [SD]: 12.2 years; range: 34–72)
and predominantly white (19 of 20, 95%); 1 participant
identified as African American. Among the 20
participants, 13 were male (65%) and the remaining 7
were female (35%); 8 participants (40%) had a previous
diagnosis of OUD, and 4 of those had a prescription for a
MOUD in the prior year. A total of 13 participants (65%)
had at least 3 opioid prescriptions in the prior year, with
an average of 7.5 prescriptions (SD: 6.6; range: 3–27).
Of these, 7 participants had received opioids for acute
needs (postsurgery or injuries), whereas 6 were on longterm opioid therapy for chronic pain. One participant
had both an OUD diagnosis and 5 opioid prescriptions
in the prior year.
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Qualitative analysis revealed 6 themes, which are
described below with corresponding representative quotes
presented in Table 1 (4 patient archetypes), Table 2 (clinic
environment), and Table 3 (opioid education).
Theme 1 — Patient Relationships With Opioid Use
and the Health Care System Can Be Understood
Using an Archetypal Heuristic (Table 1)

Archetypes do not reflect a definitive type of a patient
or relationship, but characteristics that were commonly
found together. Thus, archetypes can provide an initial
indicator PCCs may consider when engaging with their
patients about opioids and OUD risk. Patients approached
the topic of opioids differently depending on their
experience and relationship with opioids and the health
care system. Our sample yielded 4 archetypal groupings
characterizing patient relationships with opioids (Table
4) that varied in perceptions of their perceived risks for
problems with opioids, their indication for using opioids,
their views about why others might use opioids, their
beliefs about whether they have a substance use disorder,
and their openness to treatment for OUD.
Archetype 1: A self-recognized dependence on opioids
perceived as necessary for functioning in daily life,
often to manage chronic pain. This archetype fits well
with patients who reported that they have used opioids
for a long term and have not found viable alternatives
to manage their pain. Patients with statements consistent
with this archetype acknowledged a dependency on
opioids to function. However, they also characterized
themselves as different from people with OUD and
worried system-level policies to reduce opioid prescribing
would negatively affect them. They interpret actions taken
by health systems that treat them as though they have a
substance use disorder as offensive. Furthermore, they
often blame the difficulties in obtaining opioid treatment
on people with OUD.
Archetype 2: An acute use of opioids, often after
surgeries or procedures, with a corresponding selfperception of low risk for harm or addiction. Patient
responses consistent with this archetype described
short-term, acute opioid use that stopped when they
were no longer necessary to manage pain. They do not
see themselves as at risk for problems with opioids and
believe there is limited addiction potential with their
short-term use. Despite their beliefs that they have low
likelihood of developing addiction, some patients noted
frustration with being able to get opioids when they feel
they are needed. Because they see themselves as low risk,
some patients may not fully engage in that conversation.
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Table 1.  Example Quotes From Theme 1 (Archetypes of Patient Relationships With Opioid Use and the Health
Care System)
Theme

Quote

Archetype 1:
Opioids used
by patients for
chronic pain

“Well, it’s kind of hard to say because I really needed the pills to function. I really did. I was in so much
pain.” [58-year-old female]
“The abuse, I know, happens. I know there’s a lot of people who abuse it. And that’s really hard for
those of us who need it and do everything we can to limit the amount that we take. It’s kind of almost a
slap in the face because other people are abusing it.” [58-year-old male]
“And like I say, the legitimate users are going to get caught up in the whole push to get this nation off
opioids.” [63-year-old male]
“It scares me because literally not having that pain medication, or something that would work as
effectively, I can’t lift heavy stuff. I can’t make a decent living. So it did scare me because it’s important
for me to keep work [sic] and to not feel the pain in my back and shoulders.” [47-year-old male]
“I did actually need them. And when I would talk about wanting to go up, [my doctor] said something
like, ‘Well, now you sound like an addict.’ And that was really offensive, but at the same time, it was
true.” [42-year-old male]
“I don’t want to be on any of the drugs … but there’s no alternative. You name it, we’ve tried it.”
[64-year-old male]

Archetype 2:
“I take them as little as possible. I do not like that feeling. But I’ve had it for a short period of time after
Acute use of
brain aneurysm repair; I took it for maybe two days, day and night. And then just two or three nights
opioids by patients just so I could sleep after a knee replacement, for maybe a day or two after shoulder repair, and I took
it for a day or so after the broken wrist surgery. But I don’t like the feeling when I’m taking it.” [72-yearold female]
“As soon as I didn’t need them, I didn’t use them … after the second operation, when they removed
the osteo in my leg, I really wasn’t in any more pain … I had already stopped taking them at that point.”
[67-year-old male]
“Absolutely no worries have I ever had with regard to developing a risk. In fact, I had had a prescription
for Tramadol in the past. I had had a prescription for 30 pills, which took me over a year to use. And
I kept using this as an example for my responsibility factor in getting on board with another pain
medication. And that didn’t seem to have any bearing on anything. And again, I understand there are
procedures and policies, et cetera, involved with the entire group of opioid medications. But I felt like
I was kind of being treated in a punitive manner in order to be able to just get access to something,
in order to be able to assist me with pain that I was having with my back, which was documented.”
[61-year-old male]
“I didn’t have any worries because I didn’t think I was going to be on them long enough to get addicted
to them.” [72-year-old female]
“I would probably check out of that conversation [about opioid risks]. Because I never really saw myself
that way.” [43-year-old female]
Archetype 3:
Problematic
opioid use leading
to openness to
treatment for
an opioid use
disorder diagnosis

“Well, eventually I needed stronger medications because they weren’t working, and then eventually, my
doctor at the time, sent me to a pain clinic. And then they were being monitored, and then we thought
it was time for me to go off of them, and I kept getting violently ill every time I’d go off of them. And we
just were having a hard time tapering me off of them, and so I just started to do research on my own.
And I would ask questions.” [40-year-old female]
“I went to my doctor at [clinic name] … to find out how I can get off of opioids, and he referred me to Dr.
[name] because Dr. [name] is involved in the program of administering a medication that can help me
get off the pills and stop the cravings and the withdraw [sic] symptoms. And so I made my appointment
with him. So he prescribed this medication. It just helped me so much immediately. And so yeah, I kind
of looked to him as like a savior at this point because it really, really helped me.” [58-year-old female]
“I knew I had a problem … I said [to physician], ‘Okay, I want to get off [opioids]. So, if I want to get off
them and you have the support system, then I will get off them.’” [42-year-old male]

Archetype 4:
Problematic opioid
use not yet open
to treatment for
an opioid use
disorder diagnosis

“… they would at least respond with a ‘I’m not ready’ or ‘Can we give it a little longer?’ And there are so
many people out there who just want to stay on this stuff [opioids]. And I get that, I do, because it does
give some sort of semblance of normalcy.” [39-year-old male]
“Now, like I said, I’m an addict/alcoholic, and I seek opioids at certain times in my life because there
are certain doctors, word is out … ‘well, go to Dr. so-and-so at such and such a clinic to get your
meds.’ I don’t go to [my primary care clinician] for that reason. I go to him for medical reasons only. I’ve
never asked him for opioids, and I won’t because there are certain doctors, that’s why you visit them.
And then you have your other doctors for medical reasons, which he is.” [66-year-old male]
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Archetype 3: Opioid use patterns self-recognized as
problematic and leading to serious impairment or
distress and accompanied by an openness to treatment.
Patient statements consistent with this archetype
acknowledged their diagnosis of OUD and perceived
treatment as necessary.
Archetype 4: Opioid use consistent with a pattern that
leads to serious impairment or distress that, whether selfrecognized or not, is not accompanied by an openness
to treatment. Patient statements consistent with this
archetype expressed a desire to hide their problematic
opioid use and seek out different PCCs who are known to
be more liberal in prescribing opioids. They use opioids
to satisfy a craving or a use disorder.
All patients who made statements consistent with the
chronic pain on long-term opioids archetype and most
patients (5 of 6) who made statements consistent with the
acute prescription archetype were identified for the study
based on having ≥3 opioid prescriptions in the past year.
All patients with OUD on a MOUD made statements
consistent with the OUD and open-to-treatment
archetype. Of 4 people with an OUD diagnosis and no
MOUD, 2 made statements consistent with the OUD-notyet-open-to-treatment archetype. The only patient with
≥3 prescriptions and an OUD diagnosis did not clearly fit
with the acute prescription archetype (Archetype 2) or the
OUD-not-yet-open-to-treatment archetype (Archetype
4). Similarly, 1 patient with an OUD diagnosis and no
prescriptions (opioids or MOUDs) made statements
consistent with both the acute prescription (Archetype 2)
as well as the OUD-not-yet-open-to-treatment (Archetype
4) archetypes.
Theme 2 — Patients May Develop Archetypes of
PCCs, Characterized by Perceptions of Each PCC’s
Role in Their Care (Table 2)

Patients described developing a sense of a PCC’s
willingness or unwillingness to prescribe opioids. As
noted in the description of Archetype 4 (problematic
opioid use that is not treated), some patients will only
see their PCCs for medical reasons but will seek “dope
doctors” or PCCs who more freely prescribe opioids.
Theme 3 — Patients Are Open to Talking About
OUD Risk but Have Diverse Preferences for (A)
How Conversations Should Be Conducted, (B) Who
With, and (C) What Terminology Is Used (Table 2)

Analysis of our sample suggested that patients
preferred talking about opioid risks with a trusted PCC
or one who is about to prescribe opioids for them.
These conversations should be “gentle” (ie, come
from a place of empathy and compassion without
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judgment), emphasize information, and respect patient
autonomy. Patients stated PCCs should approach these
conversations with a caring attitude, transparency, and
honesty. Many patients said conversations go poorly
when PCCs talk down to them or use accusatory tones.
Ultimately, patients recommended PCCs emphasize
information-sharing and be nonaccusatory when talking
about opioid risks.
Patients varied in their comfort with different terminology.
Some patients noted feeling uncomfortable with words
like “addiction” and “dependence.” Other patients did
not share these negative feelings and emphasized how
their personal or professional backgrounds shaped their
views. Patient reactions to specific words may correlate
with their best-fitting archetype as well as their personal
and professional experiences with opioids and substance
use disorders.
Theme 4 — Primary Care Is an Appropriate Place
to Discuss Opioid Risk Because PCCs Are Trusted
Experts Who Know Their Patients Well (Table 2)

Many patients stated they preferred their PCCs discuss
opioids with them because of their trusting relationships
and some expected PCCs to discuss opioid risks regardless
of whether opioid medications were to be prescribed.
Further, patients thought PCCs should discuss opioid
risk because they manage a person’s overall health. Two
patients noted the limits of PCCs’ abilities, identifying
specialists (eg, pain management) as more appropriate
for these discussions.
Theme 5 — Patients Have Limited Awareness of
Opioid Rescue Medications and MOUDs (Table 3)

In response to questions about whether PCCs had
talked to them about having rescue medications at
home, half of the patients said they had never heard
of them before. Despite limited awareness of rescue
drugs like naloxone or MOUDs like buprenorphine,
patients at increased risk for problems with opioids
do think PCCs should be up front about offering these
options. Another patient noted she was unaware that
MOUDs were available prior to starting them and
thinks PCCs should raise awareness of the availability
of these medications.
Theme 6 — Handouts May Be More Welcomed by
Patients if Perceived to Come From PCC Judgment
Rather Than a Computer Algorithm (Table 3)

Patients were generally accepting of receiving a
handout encouraging them to discuss opioid risks with
their PCC during their visit. Several patients expressed
general acceptance of receiving a handout from a PCC;
however, when asked if they knew a computer algorithm
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Table 2.  Example Quotes From Themes 2, 3, and 4 (Clinic Environment)
Theme

Quote

Theme 2:
Patients develop
their own clinician
archetypes

“But a lot of people come up here for the wrong reasons: welfare, free housing, dope doctors.
That’s what we call them. And there’s a lot of them still practicing here in the cities like there are,
I’m sure, in a lot of other states also.” [66-year-old male]
“I think a lot of clinicians just won’t even prescribe [opioids]. And it seems like every doctor or
[physician assistant] has their own ceiling about them.” [59-year-old male]
“Well, of course [doctors] have different viewpoints. Well, maybe not viewpoints but different
methods of working with the patient. I think they each have their own strategies.” [66-year-old
female]

Theme 3:
Most patients are open
to talking about opioid
risks but have diverse
preferences on how
these conversations
should be conducted

“Just to talk with the patient in a caring way and basically letting them know that any of this
discussion is information. And so it’s not accusatory, it’s just information.” [59-year-old male]
“I know some people are a little more delicate when it comes to [talking about opioids], so I would
say knowing your patients and being tactful in your approach.” [33-year-old male]
“Well, I guess the doctor’s personality, to start with, if he's just going – if he’s just textbook and
doesn’t seem really caring, doing it because he had to, I think that would give me a bad taste.”
[66-year-old male]
“If the provider was able to approach it with always positive intentions and assuming transparency
and honesty, that might make it go better.” [34-year-old male]
“I think dependency and addiction to me sound more like risks of the prescription, and misuse
sounds more like problems I might have myself, that I might cause or that I might do to myself. So
that has a slight accusatory connotation I think to it. Where the other ones feel like side effects that
could be unintended. None of them seem bad.” [34-year-old male]
“So when you say addicted, it’s such a negative word. And when you say misuse, it seems very
deliberate when you’re telling a patient, ‘You’re misusing. You’re deliberately doing something
wrong.’” [60-year-old female]
“I used to feel really badly about that word [addict], actually, because I had always used it for my
mom and people who I thought put themselves in a situation to become an addict. So I actually
prefer the word dependent -- opiate dependent over addict, for me – to refer to me. … I guess I
would rather say, ‘You can become a dependent.’ Those wordings, I guess, I like better.” [40-yearold female]
“Addiction would give me a bad feeling.” [59-year-old male]
“[Conversations go poorly] if there’s more of a blaming attitude to it or an assumption. If that were
me, I feel distance between the doctor and myself, threatened.” [66-year-old female]
“I guess for the relationship that I have with [my PCC], I go see him about everything, so if he
wanted to talk about opioids he could.” [42-year-old male]
“I understand [opioid problems] … coming from a family of people with addiction issues, it wouldn’t
faze me personally. I would understand what they were trying to convey.” [47-year-old male]
“Just by the way they would speak about [opioids] and it made me feel like if I had to take
them that I’m some sort of, I don’t know, lower than them or just that, some sort of criminal or
something.” [59-year-old male]

Theme 4:
Primary care is an
appropriate setting for
these discussions

“Oh, my primary care. I trust him and his judgment more than anything.” [58-year-old male]
“I think it’s 100% important [for doctor to have these conversations]. And I think all of your doctors
should be in contact with each other, especially your primary care doctor should know who your
other doctors are in all of your care, and any medications they’re prescribing you, like a psychiatrist
or somebody doing methadone maintenance. Any doctor that’s involved in your health care, your
primary should know all of them and what they’re prescribing.” [40-year-old female]
“I would say it’s extremely important [for primary care doctors to talk about opioid risks]. And then
your primary care physician is your interface with the system. So this is the person you rely upon
for medical advice. And they know you. They have a relationship with you.” [67-year-old male]
“First of all, I trust [my PCC]. I trust her ability to advise me in any fashion. Plus, she has an overall
view of what I’m going through with respect to any degree of my medical history.” [61-year-old
female]
“And they should say, ‘Hey, you need to go see a specialist – a pain doctor – and let them do what
they do to figure out how much your dosage should be.’ I don't think a primary care one should be
– he’s only got limits. That’s why they have specialists.” [64-year-old male]
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Table 3.  Example Quotes From Themes 5 and 6 (Opioid Education)
Theme

Quote

Theme 5:
Patients have limited
awareness of opioid
rescue medications
and medications for
opioid use disorder

“No. Nobody’s mentioned [Narcan].” [66-year-old female]

Theme 6:
Handouts are
acceptable when
they come from the
clinician

“Fine … I think [the messages on the handouts are] pretty routine. And so I didn’t have any
emotional, positive or negative, just seemed kind of routine.” [34-year-old male]

“I’ve never heard of [Narcan].” [43-year-old female]
“[Narcan] doesn’t ring a bell, no.” [34-year-old male]
“Another thing I think that would help addicts is a lot of them don’t know about the medications that
help you stay off opioids … If I would’ve known that there were medications out there, I possibly
would've talked to my doctor about it.” [58-year-old female]

“Oh [getting a handout would] be fine. Like I was saying, [my doctor]’s honest, I value his opinion,
and he elicits the conversation out of you to answer questions that he needs answered, and I need
answered, too.” [63-year-old male]
“Well, personally in this moment in this body in this soul, I would be fine with [getting a handout]. I’d
be like, ‘Oh, that’s okay, I’ll read that.’ But I’m pretty easygoing. There are a lot of people out there
who’d probably be like, ‘What the hell? What are they trying to say?’ There could be people who take
it wrong. There’s [sic] so many not-balanced people out there that it would be offensive coming from
a computer, not a human.” [39-year-old male]
“Well, the computer doesn’t know me. The computer’s working off of information that is input into it
by someone who doesn’t know me.” [33-year-old male]

had generated the handout for them, they were more
suspect because the computer does not “know” them
like a person does.

DISCUSSION

This study aimed to learn how patients view conversations
with a clinician about opioid risks in primary care to help
PCCs think about their approach to these discussions in a
more organized and sensitive way. Analysis of the sample
identified 6 themes that could help in addressing patients
that PCCs may see; the appropriateness of the setting,
conversation, and terminology; and opioid education
needs. These themes extend the literature on opioid risk
conversations by including diverse perspectives from
patients who may be at risk for problems with opioids,
including people with chronic pain on long-term opioid
therapy, people who use opioids acutely, and people with
OUD who are and are not receiving treatment. Most
patients felt conversations with PCCs were acceptable
but preferred those conversations came from a place of
empathy and compassion and avoided stigmatizing or
judging patients.
Our findings suggest that a heuristic with at least
4 archetypes may assist PCCs in having effective
conversations with patients about opioid use risks,
particularly for persons with chronic pain on long-term
opioid therapy who are at greater risk of OUD and
harm from opioids.18 Consistent with previous research,
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individuals with characteristics consistent with this
archetype may object to being labeled as someone with
a substance use disorder.13 Further, they report frequent
experiences of being stigmatized by PCCs and having
their experiences invalidated.19,20 PCCs working with
patients making statements consistent with this archetype
may consider how their actions to mitigate opioid risks
may be perceived instead as threatening. Emphasizing
personal concern for patient safety and validating
patients’ experiences of pain may be particularly helpful
with patients in this archetype.
Across archetypes, patients wanted to be treated with
respect and compassion and to feel heard. In general,
patients recommended that PCCs approach conversations
about opioid risks with genuine concern, taking patients’
specific situations into account. Patients want their
PCCs to listen to their perspectives before switching to
a new treatment plan.21 Patient-clinician interactions are
deemed to be more collaborative when PCCs are more
compassionate, patient-centered, nonjudgmental, and
validating of patients’ concerns.9
PCCs should be reassured that patients with elevated
risk for opioid problems feel that primary care is an
appropriate setting in which to discuss opioid risks,
especially with trusted clinicians. Further, patients find it
acceptable to receive a handout prompting a discussion
about opioid risks from their PCC. Patients who
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Table 4. Characteristics of Patient Archetypes
History of
long-term
opioid use

Open to
substance
use disorder
treatment

Self-perceived
risk of problems
with opioids

Use of opioids
perceived as
necessary to
manage pain

1. People with chronic pain

Yes

No

No

Yes

2. People who use opioids acutely

No

No

No

Yes

3. People with opioid use disorder and open
to treatment

Yes

Yes

Yes

No

4. People with opioid use disorder and are
not yet open to treatment

Yes

No

No

No

Archetype

trust their PCCs are more accepting of limitations on
opioids22 and feel less stigmatized.13 Patients are more
likely to trust PCCs who demonstrate care, empathy,
and respect.23 Thus, patients trust PCCs who display a
level of interpersonal competence and are more likely
to follow their clinical recommendations. However,
repeated negotiations about opioid use can erode
those trusting relationships.24 Continued listening and
collaboration are key to maintaining positive patientPCC relationships.

overdose rescue medications or MOUDs were available
options. This is consistent with other research that
demonstrates that most people feel like they are low
risk for problems with opioids, such as an overdose, but
believe clinicians should offer naloxone.25,26 Thus, PCCs
should be aware that some patients may not personalize
opioid risks when having these conversations but that
they should still inform patients of the availability of
MOUDs and naloxone.

Our findings indicated that personal comfort with
different terms varies across patients and archetypes.
Most people objected to stigmatized labels (like addict
or addiction) when the context was in reference to
themselves. Generally, patients did not think that the
term “dependence” carried the same stigmatizing
weight, indicated that the behavior may not be entirely
controllable, and was universally understood. As
clinical terms become more widely used among the lay
population (eg, OUD), it will be important to learn more
about how patients respond to those terms.

This study was strengthened by a robust qualitative
analytic procedure and a sample that represented different
people who may be targeted for opioid risk discussions.
Its heterogenous target population also contributed to
variability in responses and allowed us to describe the
archetypes that we found. However, this study was
limited by recruitment of patients using primary care in a
single health system, which may limit the transferability
of responses to patients in specialty settings or from other
health systems or geographic locations. Further, this is a
small, nonrandom sample of people receiving care from
1 of 8 PCCs in an integrated health system who agreed
to be interviewed; although we reached saturation in
our qualitative themes within these patients, there may
be perspectives of people who were not included in this
sample. Finally, this sample was predominantly white,
not Hispanic, and middle-older age, which limits the
generalizability of these experiences from patients who
identify as members of other racial or ethnic groups or
who are younger.

A potentially novel finding was that some patients have
their own archetypes about PCCs’ comfort in prescribing
opioids. These patients learn which clinicians in the
community are more liberal in their opioid prescribing and
see them primarily to obtain opioids while avoiding the
topic with their own PCC. Other patients also described
their personal PCCs as being overly cautious about
prescribing opioids or being willing to work with them
based on their medical history. The PCC schemas that
patients develop may ultimately affect their interactions
with PCCs, including what information they are willing
to share with them.
Study participants generally felt like they were at low
risk for problems with opioids and were not aware that
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Limitations

CONCLUSIONS

It is critical for primary care clinicians to address opioid
risks with their patients, yet conversations about opioid
risks and potential opioid use problems can be challenging
for both patients and PCCs. Our study suggests that
patients feel these conversations are improved when

Original Research

PCCs approach them with compassion and consider what
they know about the patient to tailor the conversation
to patient needs. Future research is needed to assess the
applicability of these themes in a larger sample of patients
and to observe actual interactions between clinicians and
patients about this topic.
Patient-Friendly Recap
• The U.S. opioid epidemic is pervasive, yet both
patients and primary care clinicians struggle to
discuss opioid risk. Study authors interviewed 20
“high-risk” patients to get their perspectives on
having conversations about opioid screening and
treatment at clinic visits.
• Patients’ use of opioids fell into 4 distinct types,
each requiring a different conversational approach.
Still, most patients believed that primary care is an
appropriate setting for compassionate opioid risk
discussions, which should be tailored to a patient’s
specific needs.
•P
 atients have limited awareness of available
overdose and opioid use disorder medications.
• Larger-sample and real-world research into these
themes is needed to assess applicability in actual
patient-clinician interactions.
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